Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement
Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Cardiomyopathies
Session: Rapid Fire 2 - Comorbodities
